Entera Bio
ENTX
Entera Bio (ENTX) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.06
- EPS estimate
- −$0.11
- EPS surprise
- +45.45%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 8, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 8, 2025 | −$0.11 | −$0.06 | +45.45% | $0.00 | SEC |
| Q1 2025 | May 9, 2025 | −$0.07 | −$0.06 | +14.29% | −$42,000.00 | SEC |
| Q4 2024 | Mar 28, 2025 | −$0.08 | −$0.06 | +25.00% | $40,000.00 | SEC |
| Q3 2024 | Nov 8, 2024 | −$0.05 | −$0.08 | −60.00% | $42,000.00 | SEC |
| Q2 2024 | Aug 9, 2024 | −$0.06 | −$0.06 | +0.00% | $57,000.00 | SEC |
| Q1 2024 | May 10, 2024 | −$0.06 | −$0.05 | +16.67% | $0.00 | SEC |
| Q4 2023 | Mar 8, 2024 | −$0.08 | −$0.06 | +25.00% | $0.00 | SEC |
| Q3 2023 | Nov 14, 2023 | −$0.09 | −$0.08 | +11.11% | $0.00 | SEC |
| Q2 2023 | Aug 11, 2023 | −$0.07 | −$0.08 | −14.29% | $14,000.00 | SEC |
| Q1 2023 | May 5, 2023 | −$0.12 | −$0.08 | +33.33% | $13,000.00 | SEC |
| Q4 2022 | Mar 31, 2023 | −$0.12 | −$0.10 | +13.04% | $14,000.00 | SEC |
| Q3 2022 | Nov 10, 2022 | −$0.14 | −$0.11 | +18.52% | $8,000.00 | SEC |
| Q2 2022 | Aug 11, 2022 | −$0.16 | −$0.11 | +31.25% | $51,000.00 | SEC |
| Q1 2022 | May 12, 2022 | −$0.18 | −$0.13 | +26.76% | $68,000.00 | SEC |
| Q4 2021 | Mar 8, 2022 | −$0.23 | $0.21 | +190.01% | $161,000.00 | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.12 | −$0.09 | +21.74% | $140,000.00 | — |
| Q2 2021 | Aug 16, 2021 | −$0.12 | −$0.21 | −70.32% | $109,000.00 | — |
| Q1 2021 | May 20, 2021 | −$0.12 | −$0.43 | −258.33% | $157,000.00 | — |
| Q4 2020 | Mar 18, 2021 | −$0.14 | −$0.12 | +14.29% | $200,000.00 | — |
| Q3 2020 | Nov 19, 2020 | −$0.20 | −$0.09 | +55.00% | $50,000.00 | — |
Quarterly revenue
Frequently asked questions
When did Entera Bio (ENTX) last report earnings?
Entera Bio last reported on Aug 8, 2025, covering fiscal Q2 2025.
Did ENTX beat earnings estimates?
Yes. Entera Bio reported EPS of −$0.06 for Q2 2025 against a −$0.11 estimate — a 45.45% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.